DK3606942T3 - Selvsamlende proteinnanostrukturer, der viser paramyxovirus- og/eller pneumovirus f-proteiner og anvendelse deraf - Google Patents

Selvsamlende proteinnanostrukturer, der viser paramyxovirus- og/eller pneumovirus f-proteiner og anvendelse deraf

Info

Publication number
DK3606942T3
DK3606942T3 DK18723094.1T DK18723094T DK3606942T3 DK 3606942 T3 DK3606942 T3 DK 3606942T3 DK 18723094 T DK18723094 T DK 18723094T DK 3606942 T3 DK3606942 T3 DK 3606942T3
Authority
DK
Denmark
Prior art keywords
pneumovirus
paramyxovirus
proteins
self
assembling protein
Prior art date
Application number
DK18723094.1T
Other languages
Danish (da)
English (en)
Inventor
Neil P King
David Baker
Brooke Nickerson
Lance Joseph Stewart
Laurent Perez
Antonio Lanzavecchia
Jessica Marcandalli
Jorge Fallas
Yang Hsia
Original Assignee
Univ Washington
Inst Res Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Inst Res Biomedicine filed Critical Univ Washington
Application granted granted Critical
Publication of DK3606942T3 publication Critical patent/DK3606942T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18723094.1T 2017-04-04 2018-04-03 Selvsamlende proteinnanostrukturer, der viser paramyxovirus- og/eller pneumovirus f-proteiner og anvendelse deraf DK3606942T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Publications (1)

Publication Number Publication Date
DK3606942T3 true DK3606942T3 (da) 2025-09-08

Family

ID=62116943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18723094.1T DK3606942T3 (da) 2017-04-04 2018-04-03 Selvsamlende proteinnanostrukturer, der viser paramyxovirus- og/eller pneumovirus f-proteiner og anvendelse deraf

Country Status (24)

Country Link
US (4) US11192926B2 (cg-RX-API-DMAC7.html)
EP (2) EP3606942B1 (cg-RX-API-DMAC7.html)
JP (3) JP7168938B2 (cg-RX-API-DMAC7.html)
KR (2) KR102774312B1 (cg-RX-API-DMAC7.html)
CN (3) CN115779077A (cg-RX-API-DMAC7.html)
AU (3) AU2018249533C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058794A1 (cg-RX-API-DMAC7.html)
DK (1) DK3606942T3 (cg-RX-API-DMAC7.html)
ES (1) ES3040563T3 (cg-RX-API-DMAC7.html)
FI (1) FI3606942T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251060T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073526T2 (cg-RX-API-DMAC7.html)
IL (2) IL322023A (cg-RX-API-DMAC7.html)
LT (1) LT3606942T (cg-RX-API-DMAC7.html)
MX (2) MX2019011869A (cg-RX-API-DMAC7.html)
PH (1) PH12019502276A1 (cg-RX-API-DMAC7.html)
PL (1) PL3606942T3 (cg-RX-API-DMAC7.html)
PT (1) PT3606942T (cg-RX-API-DMAC7.html)
RS (1) RS67190B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908999QA (cg-RX-API-DMAC7.html)
SI (1) SI3606942T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500317T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018187325A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
JP7818504B2 (ja) * 2019-09-04 2026-02-20 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
KR20220133911A (ko) * 2020-01-30 2022-10-05 모더나티엑스, 인크. 호흡기 바이러스 면역화 조성물
EP4103230A1 (en) * 2020-02-14 2022-12-21 University of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
KR20220142471A (ko) * 2020-02-14 2022-10-21 유니버시티 오브 워싱턴 폴리펩타이드 및 그 용도
US20230227790A1 (en) * 2020-06-09 2023-07-20 Scot R. Shepard Method of assemblying two-component virus-like particle
US20240050559A1 (en) * 2020-06-09 2024-02-15 Icosavax, Inc. Method of making virus-like particle
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
KR20230107621A (ko) * 2020-11-13 2023-07-17 아이코사백스, 인크. 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
JP2024520730A (ja) * 2021-06-07 2024-05-24 アイコサバックス, インコーポレイテッド コロナウイルスに対するウイルス様粒子ワクチン
IL310628A (en) * 2021-08-10 2024-04-01 Icosavax Inc Virus-like particle vaccine for respiratory syncytial virus
JP2025517362A (ja) 2022-05-17 2025-06-05 アイコサバックス, インコーポレイテッド パラミクソウイルス用の多価ワクチン及びその使用
EP4626470A2 (en) * 2022-11-29 2025-10-08 The Scripps Research Institute Vaccines containing novel nanoparticle scaffolds
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
TW202519273A (zh) * 2023-07-18 2025-05-16 瑞典商阿斯特捷利康公司 Rsv疫苗
CN119930762A (zh) * 2023-11-03 2025-05-06 广东蓝玉生物科技有限公司 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用
CN121758570A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
DE69924712T2 (de) 1998-03-04 2006-03-09 Exxonmobil Chemical Patents Inc., Baytown Nicht koordinierende anionen für die polymerisation von olefinen
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
US20040005672A1 (en) 2002-02-22 2004-01-08 Santi Daniel V. Heterologous production of polyketides
WO2004024744A2 (en) 2002-07-31 2004-03-25 The Board Of Trustees Of The Leland Stanford Junior University Production of glycosylated macrolides in e. coli
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン,インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
WO2012048115A2 (en) * 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
SG10201602434UA (en) 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP2766030A4 (en) 2011-10-12 2015-09-16 Univ Washington MANIPULATED OUTER DOMAIN OF HV-GP120 AND MUTANTS THEREOF
WO2013155205A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
KR20150085843A (ko) 2012-11-20 2015-07-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Rsv f 융합전 삼합체
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN104436202B (zh) 2013-09-12 2017-07-28 中国科学院深圳先进技术研究院 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法
JP2016533332A (ja) 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
AU2015205567B2 (en) 2014-01-09 2019-04-04 Alpha-O Peptides Ag Flagellin-containing protein nanoparticles as a vaccine platform
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
KR102463632B1 (ko) 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
US10024198B2 (en) 2015-08-13 2018-07-17 Echogen Power Systems, Llc Heat engine system including an integrated cooling circuit
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
WO2017066484A2 (en) 2015-10-13 2017-04-20 Carter Daniel C Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
SG11201803581VA (en) 2015-10-29 2018-05-30 Univ Emory Chimeric RSV, Immunogenic Compositions, and Methods of Use
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN107157933B (zh) 2017-05-04 2021-05-11 同济大学 一种蛋白自组装新型纳米疫苗及其制备方法
CN112088014B (zh) 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗

Also Published As

Publication number Publication date
SG11201908999QA (en) 2019-10-30
KR20240161683A (ko) 2024-11-12
RS67190B1 (sr) 2025-10-31
CN115779077A (zh) 2023-03-14
MX2019011869A (es) 2020-01-09
SMT202500317T1 (it) 2025-11-10
FI3606942T3 (fi) 2025-08-29
US20250263445A1 (en) 2025-08-21
CA3058794A1 (en) 2018-10-11
PT3606942T (pt) 2025-09-01
BR112019020661A2 (pt) 2020-05-05
US11732011B2 (en) 2023-08-22
RU2019130167A3 (cg-RX-API-DMAC7.html) 2021-12-22
PH12019502276A1 (en) 2020-09-28
KR20190140916A (ko) 2019-12-20
KR102774312B1 (ko) 2025-03-05
JP2024160321A (ja) 2024-11-13
AU2018249533A1 (en) 2019-10-17
JP7168938B2 (ja) 2022-11-10
IL322023A (en) 2025-09-01
EP3606942A1 (en) 2020-02-12
US12275757B2 (en) 2025-04-15
PL3606942T3 (pl) 2025-11-12
WO2018187325A1 (en) 2018-10-11
HUE073526T2 (hu) 2026-01-28
IL269643B1 (en) 2026-07-01
AU2022202787A1 (en) 2022-05-19
SI3606942T1 (sl) 2025-11-28
US11192926B2 (en) 2021-12-07
MX2023004704A (es) 2023-05-09
AU2024220089A1 (en) 2024-10-17
US20240150411A1 (en) 2024-05-09
RU2019130167A (ru) 2021-05-05
LT3606942T (lt) 2025-10-10
AU2018249533B2 (en) 2022-01-27
IL269643A (en) 2019-11-28
AU2022202787B2 (en) 2024-07-04
AU2018249533C1 (en) 2023-10-12
AU2022202787C1 (en) 2025-01-30
EP3606942B1 (en) 2025-06-11
EP4559869A3 (en) 2025-08-20
ES3040563T3 (en) 2025-11-03
HRP20251060T1 (hr) 2025-11-07
JP2023002680A (ja) 2023-01-10
US20200392187A1 (en) 2020-12-17
CN110603262A (zh) 2019-12-20
JP2020515280A (ja) 2020-05-28
CN115947873A (zh) 2023-04-11
US20220169681A1 (en) 2022-06-02
JP7541701B2 (ja) 2024-08-29
EP4559869A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
IL269643A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
IL262652A (en) Gdf15 fusion proteins and uses thereof
IL268593A (en) Polypeptide variants and uses thereof
DK3355701T3 (da) Væskeformig ernæringssammensætning, der omfatter micellært kasein og hydrolyseret valleprotein
IL271275A (en) Compositions comprising curons and uses thereof
PT3694529T (pt) Proteínas triespecíficas e métodos de utilização
EP3675892A4 (en) IMMUNOSTIMULATORY FUSION MOLECULES AND THEIR USES
HUE054201T2 (hu) PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk
DK3707261T3 (da) Fusionsproteiner baseret på humant ferritin og protease-spaltbare peptider og deres anvendelse som kemoterapi-bærestoffer
FI3494134T3 (fi) Muunneltuja polypeptidejä ja niiden käyttötapoja
DK3596116T3 (da) Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf
BR112017024899A2 (pt) proteínas de ligação trispecíficas e métodos de uso.
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
HRP20251571T1 (hr) Rekombinantni virus humane/goveđe parainfluence 3 (b/hpiv3) koji eksprimira kimerični protein rsv/bpiv3 f i njegove uporabe
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
DK3430129T3 (da) Kolonidannende medium og anvendelse deraf
HUE042054T2 (hu) UspA2-fehérjekonstrukciók és alkalmazásuk
SI3565828T1 (sl) SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
EP3613772A4 (en) SPECIFIC BINDING MOLECULE FOR LRIG-1 PROTEIN AND ITS USE
HUE053349T2 (hu) Töréselemzõ készülék és eljárás
SI3290441T1 (sl) RGMA-vezavni protein in njegova uporaba
CL2016001921A1 (es) Proteínas inmovilizadas y uso de las mismas
EP3399033A4 (en) PEPTIDE MARKING AND MARKED PROTEIN THEREOF
EP3902556A4 (en) IN VIVO MANIPULATED CEREBLON PROTEIN
EP3498726A4 (en) DNA-BINDING PROTEIN WITH PPR MOTIF AND USE OF THE DNA-BINDING PROTEIN